LIPOCALIN FAMILY PROTEIN

Abstract: The invention provides a mammalian nucleic acid molecule and fragments thereof encoding a lipocalin. It also provides for the use of the mammalian nucleic acid molecule for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with gene expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecule.

Description: LIPOCALIN FAMILY PROTEIN TECHNICAL FIELD This invention relates to nucleic acid molecule and amino acid sequences of a new mammalian protein and to their use in the characterization, diagnosis, prevention, and treatment of conditions such as cell proliferative and immune disorders. BACKGROUND OF THE INVENTION Phylogenetic relationships among organisms have been demonstrated many times, and studies from a diversity of prokaryotic and eukaryotic organisms suggest a more or less gradual evolution of biochemical and physiological mechanisms and metabolic pathways. Despite different evolutionary pressures, proteins that regulate the cell cycle in yeast, nematode, fly, rat, and man have common chemical and structural features and modulate the same general activity. Comparisons of human gene sequences with those from other organisms where structure and/or function are known allow researchers to draw analogies and to develop model systems for testing diagnostic and therapeutic agents for human conditions, diseases, and disorders. The lipocalins are a family of extracellular ligand-binding proteins which bind and transport small hydrophobic molecules. Lipocalins function in a variety of processes including nutrient transport, cell growth regulation, immune response, and prostaglandin synthesis. Members of the lipocalin family display unusually low levels of overall sequence conservation. Pairwise sequence identity often falls below 20%, the threshold for reliable alignment. Sequence similarity between family members is limited to conserved cysteines which form disulfide bonds and three motifs which form a juxtaposed cluster that functions as a target cell recognition site. The lipocalins share an eight stranded, anti-parallel beta-sheet which folds back on itself to form a continuously hydrogen-bonded beta-barrel. The pocket formed by the barrel functions as an internal ligand binding site. Seven loops (LI to L7) form short beta-hairpins, except loop LI which is a large omega loop that forms a lid to partially close the internal ligand-binding site (Flower (1996) Biochem. J. 318:1-14). Lipocalins are important transport molecules. Each lipocalin associates with a particular ligand and delivers that ligand to appropriate target sites within the organism. Retinol-binding protein (RBP), one of the best characterized lipocalins, transports retinol from stores within the liver to target tissues. Apolipoprotein D (apo D), a component of high density lipoproteins (HDLs) and low density lipoproteins (LDLs), functions in the targeted collection and delivery of cholesterol throughout the body. Lipocalins also are involved in cell regulatory processes. Apo D, which is identical to gross-cystic-disease-fluid protein (GCDFP)-24, is a progesterone/pregnenolone-binding protein expressed at high levels in breast cyst fluid. Secretion of apo D in certain human breast cancer cell lines is accompanied by reduced cell proliferation and progression of cells to a more differentiated phenotype. Similarly, apo D and another lipocalin, α,-acιd glycoprotein (AGP), are involved in nerve cell regeneration. AGP is also involved in anti-inflammatory and immunosuppressive activities AGP is one of the positive acute-phase proteins (APP), circulating levels ot AGP increase in response to stress and inflammatory stimulation AGP accumulates at sites of inflammation where it inhibits platelet and neutrophil activation and inhibits phagocytosis The immunomodulatory properties of AGP are due to glycosylation AGP is 40% carbohydrate, making it unusually acidic and soluble The glycosylation pattern ot AGP changes during acute-phase response, and deglycosylated AGP has no immunosuppressive activity (Flower (1994) FEBS Lett. 354 7-11 , Flower, supra). Lipocalins are used as diagnostic and prognostic markers in a variety of disease states The plasma level ot AGP is monitored duπng pregnancy and in diagnosis and prognosis ot conditions including cancer chemotherapy, renal disfunction, myocardial intarction, arthritis, and multiple sclerosis RBP is used clinically as a marker ot tubular reabsorption in the kidney, and apo D is a marker in gross cystic breast disease (Flower (1996) supra) The discovery ot mammalian nucleic acid molecules encoding a lipocalin tamily protein provides new compositions which are useful in the characterization, diagnosis, prevention, and treatment ot cell prohferative and immune disorders. SUMMARY OF THE INVENTION The invention is based on the discovery of a substantially purified mammalian nucleic acid molecule encoding a mammalian protein, lipocalin tamily protein (LCFP), which satisfies a need in the art by providing compositions useful in the characterization, diagnosis, prevention, and treatment of conditions such as cell prohferative and immune disorders The invention provides isolated and purified human and rat nucleic acid molecules comprising SEQ ID NOs.l and 10, and fragments thereof SEQ ID NOs 3-9, encoding the mammalian protein compnsmg amino acid sequences of SEQ ID NOs.2 and 11, or portions thereof. The invention further provides a probe which hybridizes under high stringency conditions to the mammalian nucleic acid molecule or fragments thereof. The invention also provides isolated and purified nucleic acid molecules which are complementary to the nucleic acid molecules of SEQ ID NOs 1 and 3-10 In one aspect, the probe is a single stranded complementary RNA or DNA molecule The invention further provides a method for detecting a nucleic acid molecule in a sample, the method comprising the steps of hybridizing a probe to at least one nucleic acid molecule of a sample, forming a hybridization complex; and detecting the hybridization complex, wherein the presence of the hybridization complex indicates the presence of the nucleic acid molecule in the sample. In one aspect, the method further comprises amplifying the nucleic acid molecule pnor to hybridization The nucleic acid molecule or a fragment thereof may comprise either an element or a target on a microarray The invention also provides a method for using a nucleic acid molecule or a fragment thereof to screen a library of molecules to identify at least one ligand which specifically binds the nucleic acid molecule, the method comprising combimng the nucleic acid molecule with a library of molecules under conditions allowing specific binding, and detecting specific binding, thereby identifying a ligand which specifically binds the nucleic acid molecule Such libraries include DNA and RNA molecules, peptides, PNAs, proteins, and the like In an analogous method, the nucleic acid molecule or a fragment thereof is used to purify a ligand The invention also provides an expression vector containing at least a fragment of the nucleic acid molecule In another aspect, the expression vector is contained within a host cell The invention further provides a method for producing a protein, the method comprising the steps of cultunng the host cell under conditions for the expression of the protein and recovering the protein from the host cell culture The invention also provides a substantially purified mammahan lipocalin family protein or a portion thereof The invention further provides isolated and purified proteins having the amino acid sequences of SEQ ID NOs.2 and 11. Additionally, the invention provides a pharmaceutical composition comprising a substantially purified mammalian protein or a portion thereof in conjunction with a pharmaceutical carrier. The invention further provides a method for using at least a portion of the mammalian protein to produce antibodies The invention also provides a method for using a mammalian protein or a portion thereof to screen a library ot molecules to identify at least one ligand which specifically binds the protein, the method comprising combimng the protein with the library of molecules under conditions allowing specific binding, and detecting specific binding, thereby identifying a ligand which specifically binds the protein. Such libraries include DNA and RNA molecules, peptides, agomsts, antagonists, antibodies, immunoglobulins, drug compounds, pharmaceutical agents, and other hgands. In one aspect, the ligand identified using the method modulates the activity of the mammalian protein. In an analogous method, the protein or a portion thereof is used to purify a ligand. The method involves combimng the mammalian protein or a portion thereof with a sample under conditions to allow specific binding, detecting specific binding between the protein and ligand, recovering the bound protein, and separating the protein from the ligand to obtain purified ligand The invention further provides a method for inserting a marker gene into the genomic DNA of a mammal to disrupt the expression of the natural mammalian nucleic acid molecule. The invention also provides a method for using the mammalian nucleic acid molecule to produce a mammalian model system, the method comprising constructing a vector contaimng the mammalian nucleic acid molecule, introducing the vector into a totipotent mammalian embryonic stem cell, selecting an embryonic stem cell with the vector integrated into genomic DNA. mιcroιn)ectιng the selected cell into a mammalian blastocyst, thereby forming a chimeπc blastocyst, transferring the chimeπc blastocyst into a pseudopregnant dam, wherein the dam gives birth to a chimeπc mammal contaimng at least one additional copy of mammalian nucleic acid molecule in its germ line, and breeding the chimeπc mammal to generate a homozygous mammalian model system BRIEF DESCRIPTION OF THE FIGURES AND TABLE Figures 1 A and IB show the human nucleic acid molecule (SEQ ID NO 1) encoding the human amino acid sequence (SEQ ID NO 2) of the mammalian protein The alignment was produced using MACDNASIS PRO software (Hitachi Software Engineenng, South San Francisco CA) Figures 2A and 2B show the rat nucleic acid molecule (SEQ ID NO 10) encoding the rat amino acid sequence (SEQ ID NO 1 1 ) of the mammalian protein The alignment was produced using MACDNASIS PRO software (Hitachi Software Engineering) Figure 3 demonstrates the chemical and structural similarity among human, 28565127 (SEQ ID NO 2), rat, 700046753 (SEQ ID NO 1), and mouse NG20, g3941735 (SEQ ID NO 12) proteins, produced using the MEG ALIGN program (DNASTAR, Madison WI) Table 1 compares Incyte rat and human nucleic acid molecules including their length, biological source, region of overlap with SEQ ID NO 1, and percent identity with SEQ ID NO 1 (MEGALIGN program, DNASTAR). DESCRIPTION OF THE INVENTION It is understood that this invention is not limited to the particular machines, materials and methods descπbed It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. As used herein, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise For example, a reference to "a host cell" includes a plurality of such host cells known to those skilled in the art Unless defined otherwise, all technical and scientific terms used herein have the same meamngs as commonly understood by one of ordinary skill in the art to which this invention belongs All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention Definitions "Lipocalin family protein (LCFP)" refers to a substantially purified protein obtained from any mammalian species, including murine, bovine, ovine, porcine, rodent, camne, simian, and preferably the human species, and from any source, whether natural, synthetic, semi-synthetic, or recombinant "Biologically active" refers to a protein having structural, immunological, regulatory, or chemical functions of a naturally occurring, recombinant or synthetic molecule "Complementary" refer to the natural hydrogen bonding by base pairing between puπnes and pyπmidines For example, the sequence A-C-G-T forms hydrogen bonds with its complements T-G- C-A or U-G-C-A Two single-stranded molecules may be considered partially complementary, if only some of the nucleotides bond, or completely complementary, if nearly all of the nucleotides bond The degree of complementarity between nucleic acid strands affects the efficiency and strength of the hybridization and amplification reactions "Derivative" refers to the chemical modification of a nucleic acid molecule or amino acid sequence Chemical modifications can include replacement of hydrogen by an alkyl, acyl, or amino group or glycosylation, pegylation, or any similar process which retains or enhances biological activity or hfespan of the molecule or sequence "Fragment" refers to an Incyte clone or any part of a nucleic acid molecule which retains a usable, functional characteristic Useful fragments include oligonucleotides which may be used in hybridization or amplification technologies or in regulation of replication, transcnption or translation "Hybridization complex" refers to a complex between two nucleic acid molecules by virtue of the formation of hydrogen bonds between puπnes and pyπmidines "Ligand" refers to any molecule, agent, or compound which will bind specifically to a complementary site on a nucleic acid molecule or protein Such hgands stabilize or modulate the activity of nucleic acid molecules or proteins of the invention and may be composed of at least one of the following, inorgamc and orgamc substances including nucleic acids, proteins, carbohydrates, tats, and pids "Modulates" refers to a change in activity (biological, chemical, or immunological) or hfespan resulting from specific binding between a molecule and either a nucleic acid molecule or a protein "Nucleic acid molecule" refers to a nucleic acid, o gonucleotide, nucleotide, polynucleotide or any fragment thereof. It may be DNA or RNA of genomic or synthetic origin, double-stranded or single-stranded, and combined with carbohydrate, lipids, protein or other mateπals to perform a particular activity such as transformation or form a useful composition such as a peptide nucleic acid (PNA) "Ohgonucleotide" is substantially equivalent to the terms amphmer, pnmer, oligomer, element, target, and probe and is preferably single stranded. "Protein" refers to an amino acid sequence, ohgopeptide, peptide, polypeptide or portions thereof whether naturally occumng or synthetic "Portion", as used herein, refers to any part of a protein used for any purpose, but especially for the screemng of a library of molecules which molecules which specifically bind to that portion or for the production of antibodies "Sample" is used in its broadest sense A sample contaimng nucleic acid molecules may comprise a bodily fluid, an extract from a cell, chromosome, organelle, or membrane isolated from a cell, genomic DNA, RNA, or cDNA in solution or bound to a substrate, a cell, a tissue, a tissue print, and the like. "Substantially purified" refers to nucleic acid molecules or proteins that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% tree, and most preferably about 90% tree, from other components with which they are naturally associated. "Substrate" refers to any rigid or semi-rigid support to which nucleic acid molecules or proteins are bound and includes membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, capillaries or other tubing, plates, polymers, and microparticles with a variety of surface forms including wells, trenches, pins, channels and pores THE INVENTION The invention is based on the discovery of a new mammalian nucleic acid molecule which encodes a mammalian protein, lipocalin family protein (LCFP), and on the use of the nucleic acid molecule, or fragments thereof, and protein, or portions thereof, as compositions in the characterization, diagnosis, treatment, or prevention of conditions such as cell prohferative and immune disorders Nucleic acid molecules encoding the mammalian lipocalin family protein of the present invention were identified by using Blast to annotate unique clones in the ZOOSEQ database (Incyte Pharmaceuticals, Palo Alto CA) and assembling the clones with homology to mouse NG20 (SEQ ID NO.12) The clones from various rat liver braπes. 701318182H1, 700046753H1, 701427716T1, and 700608183H 1 , SEQ ID NOs.6-9, respectively; were assembled using Phrap into the consensus nucleic acid molecule, SEQ ID NO 10, which encodes the protein having the amino acid sequence of SEQ ID NO 11 (Figures 2A and 2B). PFAM confirmed the identity of SEQ ID NO.l 1 as a lipocalin family protein based on amino acid sequence identity from L148 through C 185 of SEQ ID NO.11. In addition, PRINTS identifies two lipocalin signatures in SEQ ID NO.l 1 from residues E41 through A53 and LI 48 through F163 SEQ ID NO.10 was used to identify human lipocalin family nucleic acid molecules in the Incyte LIFESEQ database (Incyte Pharmaceuticals). Incyte clones (libraries) 4069566H1 (KIDNNOT26), 4419443H1 (LIVRDIT02), and 2865127H1 (KIDNNOT20). SEQ ID NOs 3-5, respectively, contributed to the assembly of the consensus sequence, SEQ ID NO 1 (Figures 1 A and IB) Northern analysis shows expression of this molecule in various libraries, particularly digestive system (67%) and reproductive (17%) tissues. SEQ ID NO 1 has a 67% association with cancerous or proliferating tissues and a 17% association with inflamed, immune responsive, or infected tissues The nucleic acid sequences, SEQ ID NO 1, SEQ ID NO 10, and their respective fragments (SEQ ID NOs 3-9) may be used in hybridization and amplification technologies to identify and distinguish among SEQ ID NO. l, SEQ ID NO 10, and similar molecules in a sample The molecules may be used to mimic human conditions, diseases, or disorders, produce transgeruc a mal models for these conditions, or to momtor ammal toxicology studies, chmcal trials, and subject/patient treatment profiles LCFP comprises the amino acid sequences of SEQ ID NO 2, 188 amino acids in length, and of SEQ ID NO 11, 190 amino acids in length The human protein (SEQ ID NO 2) has a potential N- glycosylation site at N 135 The following chemical and structural characterization of the lipocalin family proteins will be based on absolute positions (60 residues per line) shown in Figure 3 The human, rat and mouse proteins (SEQ ID NOs.2, 1 l,and 12, respectively) share two casein kinase II phosphorylation sites at residues T56 and SI 65, two protein kinase C phosphorylation sites at residues T87 and T178, and two lipocalin signatures from residues E41 through A53 and L148 through F163. In addition, the cysteine residues, C23, C95, C130, C159, C169, and C185, essential in hpocahn disulfide bonding, and the prohne (P24, P40, P79, P97, PI 19, PI 31, P153, P155, P156, and P179), arginine (R85, R89, R98, Rl 14, R118, R145, R151, and R180) and tyrosine (Y13, Y48, Y102, Y143, and Y149) residues important in protein folding and conformation are conserved among the three mammalian species as shown in Figure 3. SEQ ID NO 2 shares 81 4% similarity with SEQ ID NO 11 and 79 8% similarity with SEQ ID NO 12 (calculated using LASERGENE software, DNASTAR) SEQ ID NOs.2 and 11 are similar in size, 21.3 kDa, and 21 5 kDa, respectively, and lsoelectnc point, pi of 5 8 and 5.9, respectively (calculated using LASERGENE software, DNASTAR) SEQ ID NO 2 is also of similar length, size, and pi to lipocalin family members human apo D (g4502163, SEQ ID NO 13, 189 amino acids, 21.3 kDa, and pi 5.0, respectively) and rat retinol binding protein (gl 13824, SEQ ID NO 14, 188 amino acids, 20J kDa, and pi 5.22, respectively). The amino acids of SEQ ID NO.2 from residue H83 to residue W100 are useful for antibody production. Characterization and Use of the Invention cDNA libraries In a particular embodiment disclosed herein, mRNA was isolated from mammalian cells and tissues using methods which are well known to those skilled in the art and used to prepare the cDNA libraπes The Incyte clones listed above were isolated from mammalian cDNA libraries At least one library preparation representative of the invention is described in the EXAMPLES below The consensus mammalian sequences were chemically and/or electronically assembled from fragments including Incyte clones and extension and/or shotgun sequences using computer programs such as Phrap (P Green, Umversity of Washington, Seattle WA), GELVIEW Fragment Assembly system (Genetics Computer Group, Madison WI), and AUTOASSEMBLER application (Perkin Elmer, Norwalk CT). Sequencing Methods for sequencing nucleic acids are well known in the art and may be used to practice any of the embodiments of the invention These methods employ enzymes such as the Klenow tragment of DNA polymerase I, SEQUENASE (USB, Cleveland OH), Taq DNA polymerase (Perkin- Elmer), thermostable T7 DNA polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Rockville MD) Preferably, sequence preparation is automated with machines such as the HYDRA microdispenser (Robbins Scientific, Sunnyvale CA), MICROLAB 2200 (Hamilton, Reno NV), and the DNA ENGINE thermal cycler (PTC200, MJ Research, Watertown MA). Machines used for sequencing include the ABI 3700, 377 or 373 DNA sequencing systems (Perkin-Elmer), the MEG AB ACE 1000 DNA sequencing system (Amersham Pharmacia Biotech), and the like The sequences may be analyzed using a variety of algorithms which are well known in the art and described in Ausubel (1997, Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, umt 7 7) and Meyers (1995. Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853) Shotgun sequencing is used to generate more sequence from cloned inserts derived from multiple sources. Shotgun sequencing methods are well known in the art and use thermostable DNA polymerases, heat-labile DNA polymerases, and primers chosen from representative regions flanking the nucleic acid molecules of interest. Prefinished sequences (incomplete assembled sequences) are inspected for identity using vanous algorithms or programs such as CONSED (Gordon (1998) Genome Res. 8.195-202) which are well known in the art. Contaminating sequences including vector or chimeπc sequences or deleted sequences can be removed or restored, respectively, organizing the prefinished sequences into fimshed sequences. Extension of a Nucleic Acid Sequence The sequences of the invention may be extended using vanous PCR-based methods known in the art. For example, the XL-PCR kit (Perkin-Elmer), nested primers, and commercially available cDNA or genomic DNA libraπes (Life Technologies; Clontech, Palo Alto CA, respectively) may be used to extend the nucleic acid sequence. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4 06 Primer Analysis software ( National Biosciences, Plymouth MN) to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to a target molecule at temperatures from about 55°C to about 68°C When extending a sequence to recover regulatory elements, it is preferable to use genomic, rather t-han cDNA libraries USE OF THE MAMMALIAN NUCLEIC ACID MOLECULE Hybridization The mammalian nucleic acid molecule and tragments thereof can be used in hybridization technologies for various purposes. A probe may be designed or derived trom umque regions such as the 5' regulatory region or from a conserved motif such as the lipocalin family signature and used in protocols to identify naturally occurring molecules encoding the mammalian protein, alle c variants, or related molecules The probe may be DNA or RNA, is usually single stranded and should have at least 50% sequence identity to any of the nucleic acid sequences Hybridization probes may be produced using oligolabe ng, ruck translation, end-labeling, or PCR amplification in the presence of labeled nucleotide A vector contaimng the nucleic acid molecule or a fragment thereof may be used to produce an mRNA probe in vitro by addition of an RNA polymerase and labeled nucleotides These procedures may be conducted using commercially available kits such as those provided by Amersham Pharmacia Biotech The stringency of hybridization is determined by G+C content of the probe, salt concentration, and temperature In particular, stringency can be increased by reducing the concentration of salt or raising the hybridization temperature In solutions used for some membrane based hybridizations, addition of an orgamc solvent such as formamide allows the reaction to occur at a lower temperature Hybridization can be performed at low stringency with buffers, such as 5xSSC with 1 % sodium dodecyl suit ate (SDS) at 60° C, which permits the formation of a hybridization complex between nucleic acid sequences that contain some mismatches Subsequent washes are performed at higher stringency with buffers such as 0 2xSSC with 0 1% SDS at either 45° C (medium stringency) or 68° C (high stringency). At high stringency, hybridization complexes will remain stable only where the nucleic acid molecules are completely complementary. In some membrane- based hybridizations, perferably 35% or most preferably 50%, formamide can be added to the hybridization solution to reduce the temperature at which hybridization is performed, and background signals can be reduced by the use of other detergents such as Sarkosyl or Triton X-100 and a blocking agent such as denatured salmon sperm DNA. Selection of components and conditions for hybndization are well known to those skilled in the art and are reviewed m Ausubel (supra) and Sambrook et al. (1989) Molecular Clomng, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY. Microarrays may be prepared and analyzed using methods known in the art O gonucleotides may be used as either probes or targets in a microarray The microarray can be used to momtor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and single nucleotide polymorphisms Such information may be used to determine gene function, to understand the genetic basis of a condition, disease, or disorder, to diagnose a condition, disease, or disorder, and to develop and momtor the activities of therapeutic agents (See, e g , Brennan et al (1995) USPN 5,474,796. Schena et al (1996) Proc Natl Acad Sci 93 10614-10619. Baldeschweiler et al (1995) PCT application W095/251116, Shalon et al (1995) PCT application WO95/35505, Heller et al (1997) Proc Natl Acad Sci 94 2150-2155, and Heller et al (1997) USPN 5,605,662 ) Hybndization probes are also useful in mapping the naturally occumng genomic sequence The probes may be hybridized to 1) a particular chromosome, 2) a specific region of a chromosome, 3) artificial chromosome constructions such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial PI constructions, or single chromosomes or 5) cDNA libraries made from any of these sources Expression A multitude of nucleic acid molecules encoding the mammalian lipocalin family protein may be cloned into a vector and used to express the protein, or portions thereof, in host cells The nucleic acid sequence can be engineered by such methods as DNA shuffling (Stemmer and Crameπ (1996) USPN 5,830,721 incorporated by reference herein) and site-directed mutagenesis to create new restriction sites, alter glycosylation patterns, change codon preference to increase expression in a particular host, produce splice variants, extend half-life, and the like The expression vector may contain transcπptional and translational control elements (promoters, enhancers, specific initiation signals, and polyadenylated 3 " sequence) from various sources which have been selected for their efficiency in a particular host The vector, nucleic acid molecule, and regulatory elements are combined using in vitro recombinant DNA techmques, synthetic techmques, and/or in vivo genetic recombination techmques well known in the art and descπbed in Sambrook (supra, ch 4, 8, 16 and 17) A variety of host systems may be transformed with an expression vector These include, but are not limited to, bacteria transformed with recombinant bacteπophage, plasmid, or cosmid DNA expression vectors, yeast transformed with yeast expression vectors, insect cell systems transformed with baculovirus expression vectors, plant cell systems transformed with expression vectors contaimng viral and/or bacterial elements, or ammal cell systems (Ausubel supra, umt 16) For example, an adenovirus transcription/translation complex may be utilized in mammahan cells After sequences are ligated into the El or E3 region of the viral genome, the infective virus is used to transform and express the protein in host cells The Rous sarcoma virus enhancer or SV40 or EBV- based vectors may also be used for high-level protein expression. Routine cloning, subcloning, and propagation of nucleic acid sequences can be achieved using the multifunctional PBLUESCRIPT vector (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Introduction of a nucleic acid sequence into the multiple cloning site of these vectors disrupts the lacL gene and allows colorimetric screening for transformed bacteria. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. For long term production of recombinant proteins, the vector can be stably transformed into cell lines along with a selectable or visible marker gene on the same or on a separate vector. After transformation, cells are allowed to grow for about 1 to 2 days in enriched media and then are transferred to selective media. Selectable markers, antimetabolite, antibiotic, or herbicide resistance genes, confer resistance to the relevant selective agent and allow growth and recovery of cells which successfully express the introduced sequences. Resistant clones identified either by survival on selective media or by the expression of visible markers, such as anthocyanins, green fluorescent protein (GFP). β glucuronidase, luciferase and the like, may be propagated using culture techniques. Visible markers are also used to quantify the amount of protein expressed by the introduced genes. Verification that the host cell contains the desired mammalian nucleic acid molecule is based on DNA-DNA or DNA-RNA hybridizations or PCR amplification techniques. The host cell may be chosen for its ability to modify a recombinant protein in a desired fashion. Such modifications include acetylation, carboxylation, glycosylation, phosphorylation, lipidation, acylation and the like. Post-translational processing which cleaves a "prepro" form may also be used to specify protein targeting, folding, and/or activity. Different host cells available from the ATCC (Bethesda, MD) which have specific cellular machinery and characteristic mechanisms for post-translational activities may be chosen to ensure the conect modification and processing of the recombinant protein. Recovery of Proteins from Cell Culture Heterologous moieties engineered into a vector for ease of purification include glutathione S- transferase (GST), calmodulin binding peptide (CBP), 6-His, FLAG, MYC, and the like. GST, CBP, and 6-His are purified using commercially available affinity matrices such as immobilized glutathione, calmodulin, and metal-chelate resins, respectively. FLAG and MYC are purified using commercially available monoclonal and polyclonal antibodies. A proteolytic cleavage site may be located between the desired protein sequence and the heterologous moiety for ease of separation following purification. Methods for recombinant protein expression and purification are discussed in Ausubel (supra, unit 16) and are commercially available. Chemical Synthesis of Peptides Proteins or portions thereof may be produced not only by recombinant methods, but also by using chemical methods well known in the art Solid phase peptide synthesis may be carried out in a batchwise or continuous flow process which sequentially adds α-amino- and side chain-protected amino acid residues to an insoluble polymeric support via a linker group A linker group such as methylamine-derivatized polyethylene glycol is attached to poly(styrene-co-dιvιnylbenzene) to form the support resin The amino acid residues are N-α-protected by acid labile Boc (t-butyloxycarbonyl) or base-labile Fmoc (9-fluorenylmethoxycarbonyl) The carboxyl group of the protected amino acid is coupled to the amine of the linker group to anchor the residue to the sohd phase support resin Tπfluoroacetic acid or pipeπdine are used to remove the protecting group in the case of Boc or Fmoc, respectively. Each additional amino acid is added to the anchored residue using a coupling agent or pre-activated amino acid derivative, and the resin is washed The full length peptide is synthesized by sequential deprotection, coupling of deπvitized amino acids, and washing with dichloromethane and or Ν, Ν-dimethylformamide The peptide is cleaved between the peptide carboxy terminus and the linker group to yield a peptide acid or amide (Νovabiochem 1997/98 Catalog and Peptide Synthesis Handbook, San Diego CA pp S1-S20) Automated synthesis may also be carried out on machines such as the ABI 431 A Peptide synthesizer (Perkin-Elmer). A protein or portion thereof may be substantially purified by preparative high performance liquid chromatography and its composition confirmed by amino acid analysis or by sequencing (Creighton (1984) Proteins. Structures and Molecular Properties, WH Freeman, New York NY). Preparation and Screening of Antibodies Various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with mammalian lipocalin family protein or any portion thereof. Adjuvants such as Freund ' s, mineral gels, and surface active substances such as lysolecithin, pluromc polyols, polyanions, peptides, oil emulsions, keyhole limpet hemacyanin (KLH), and dimtrophenol may be used to increase immunological response The ohgopeptide, peptide, or portion of protein used to induce antibodies should consist of at least about five amino acids, more preferably ten amino acids, which are identical to a portion of the natural protein. Ohgonucleotides may be fused with proteins such as KLH in order to produce antibodies to the chimeπc molecule. Monoclonal antibodies may be prepared using any techmque which provides for the production of antibodies by continuous cell lines in culture. These include, but are not limited to, the hybπdoma techmque, the human B-cell hybndoma techmque, and the EBV-hybπdoma techmque (See, e.g., Kohler et al. (1975) Nature 256.495-497, Kozbor et al. (1985) J. Immunol. Methods 81.31- 42, Cote et al. (1983) Proc. Natl. Acad. Sci. 80.2026-2030; and Cole et al (1984) Mol. Cell Biol. 62.109-120.) Alternatively, techmques descπbed for the production of single chain antibodies may be adapted, using methods known in the art, to produce epitope specific single chain antibodies Antibody fragments which contain specific binding sites for epitopes of the mammalian protein may also be generated For example, such fragments include, but are not limited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libranes may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (See, e g , Huse et al (1989) Science 246 1275-1281.) The mammalian lipocalin family protein or a portion thereof may be used in screemng assays of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies having the desired specificity Numerous protocols for competitive binding or immunoassays using either polyclonal or monoclonal antibodies with established specificities are well known in the art Such immunoassays typically involve the measurement of complex formation between the protein and its specific antibody A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes is preferred, but a competitive binding assay may also be employed (Pound (1998) Immunochemical Protocols, Humana Press, Totowa NJ) Labeling of Molecules for Assay A wide variety of labels and conjugation techmques are known by those skilled in the art and may be used in various nucleic acid, amino acid, and antibody assays. Synthesis of labeled molecules may be achieved using Promega (Madison WI) or Amersham Pharmacia Biotech kits for incorporation of a labeled nucleotide such as 32 P-dCTP, Cy3-dCTP or Cy5-dCTP (Amersham Pharmacia Biotech) or amino acid such as 3S S-methιonιne (USB, Cleveland OH) Nucleotides and amino acids may be directly labeled with a variety of substances including fluorescent, chemiluminescent, or chromogemc agents, and the like, by chemical conjugation to amines, thiols and other groups present in the molecules using reagents such as BIODIPY or FITC (Molecular Probes, Eugene OR). DIAGNOSTICS The nucleic acid molecules, fragments, ohgonucleotides, complementary RNA and DNA molecules, and PNAs may be used to detect and quantify altered gene expression, absence/presence vs. excess, expression of mRNAs or to momtor mRNA levels dunng therapeutic intervention Conditions, diseases or disorders associated with altered expression include acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondy tis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bemgn prostatic hyperplasia, bronchitis, Chediak-Higashi syndrome, cholecystitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atropfuc gastritis, glomerulonephntis, Goodpasture ' s syndrome, gout, chrome granulomatous diseases, Graves " disease, Hashιmoto " s thyroiditis, hypereosinophiha, irritable bowel syndrome, multiple sclerosis, myasthema gravis, myocardial or peπcardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polycystic ovary syndrome, polymyositis, psoriasis, Reιter " s syndrome, rheumatoid arthritis, scleroderma, severe combined immunodeficiency disease (SCID), Sjogren " s syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infection, and actimc keratosis, arteriosclerosis, bursitis, ciπhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuπa, polycythemia vera, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, perns, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus The diagnostic assay may use hybridization or amplification technology to compare gene expression in a biological sample from a patient to standard samples in order to detect altered gene expression Qualitative or quantitative methods for this companson are well known in the art. For example, the nucleic acid molecule or probe may be labeled by standard methods and added to a biological sample from a patient under conditions for the formation of hybridization complexes After an incubation penod, the sample is washed and the amount of label (or signal) associated with hybridization complexes, is quantified and compared with a standard value If the amount of label in the patient sample is significantly altered in comparison to the standard value, then the presence of the associated condition, disease or disorder is indicated In order to provide a basis for the diagnosis of a condition, disease or disorder associated with gene expression, a normal or standard expression profile is established. This may be accomplished by combimng a biological sample taken from normal subjects, either ammal or human, with a probe under conditions for hybridization or amplification Standard hybndization may be quantified by comparing the values obtained using normal subjects with values from an expenment in which a known amount of a substantially purified target sequence is used Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a particular condition, disease, or disorder. Deviation from standard values toward those associated with a particular condition is used to diagnose that condition Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in ammal studies and in chmcal trial or to momtor the treatment of an individual patient Once the presence of a condition is established and a treatment protocol is initiated, diagnostic assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in a normal subject The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months Immunological Methods Detection and quantification of a protein using either specific polyclonal or monoclonal antibodies are known in the art Examples of such techmques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS) A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfenng epitopes is preferred, but a competitive binding assay may be employed (See, e g , Cohgan et al (1997) Current Protocols in Immunology, Wiley-Interscience, New York NY, and Pound, supra ) THERAPEUTICS Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of the SEQ ID NO.2 and SEQ ID NO 1 1 and other lipocalin family proteins, human apolipoprotein D (g4502163) and rat retinol binding protein (gl 13824) In addition, gene expression is closely associated with digestive system and reproductive tissues and appears to play a role in conditions such as cell prohferative and immune disorders In the treatment of conditions associated with increased expression or activity, it is desirable to decrease expression or protein activity In the treatment of conditions associated with decreased expression or activity, it is desirable to increase expression or protein activity In one embodiment, the mammalian protein or a portion or derivative thereof may be admimstered to a subject to treat or prevent a condition associated with altered expression or activity of the mammalian protein Examples of such conditions include, but are not limited to, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondyhtis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bemgn prostatic hyperplasia, bronchitis, Chediak-Higashi syndrome, cholecystitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetahs, erythema nodosum, atrophic gastritis, glomerulonephπtis, Goodpasture's syndrome, gout, chrome granulomatous diseases, Graves' disease, Hashimoto's thyroiditis, hypereosinophi a, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or peπcardial inflammation, osteoarthntis, osteoporosis, pancreatitis, polycystic ovary syndrome, polymyositis, psonasis, Reiter's syndrome, rheumatoid arthntis, scleroderma, severe combined immunodeficiency disease (SCID), Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopemc purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infection, and actimc keratosis, arteriosclerosis, bursitis. cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuπa, polycythemia vera, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma. melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, perns, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. In another embodiment, a pharmaceutical composition comprising a substantially purified mammalian protein in conjunction with a pharmaceutical carrier may be admimstered to a subject to treat or prevent a condition associated with altered expression or activity of the endogenous protein including, but not limited to, those provided above In a further embodiment, a ligand which modulates the activity of the mammalian protein may be admimstered to a subject to treat or prevent a condition associated with altered htespan, expression, or activity of the protein including, but not limited to, those listed above In one aspect, an antibody which specifically binds the mammahan protein may be used as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express the mammalian protein In an additional embodiment, a vector capable of expressing the mammalian protein or a portion or derivative thereof may be admimstered to a subject to treat or prevent a condition associated with altered hfespan, expression, or activity ot protein including, but not limited to, those descnbed above In a still further embodiment, a vector expressing the complement of the nucleic acid molecule or fragments thereof may be admimstered to a subject to treat or prevent a condition associated with altered hfespan, expression, or activity of the protein including, but not limited to, those described above. Any of the nucleic acid molecules, complementary molecules and fragments thereof, proteins or portions thereof, vectors delivering these nucleic acid molecules or proteins, and their hgands may be admimstered in combination with other therapeutic agents Selection of the agents for use in combination therapy may be made by one of ordinary skill in the art according to conventional pharmaceutical principles. A combination of therapeutic agents may act synergistically to effect prevention or treatment of a particular condition at a lower dosage of each agent. Modification of Gene Expression Using Nucleic Acids Gene expression may be modified by desigmng complementary or antisense molecules (DNA, RNA, or PNA) to the control, 5', 3', or other regulatory regions of the mammalian gene Oligonucleotides designed with reference to the transcription initiation site are preferred Similarly, inhibition can be achieved using triple helix base-pairing which inhibits the binding of polymerases, transcription factors, or regulatory molecules (Gee et al In Huber and Carr (1994) Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177) A complementary molecule may also be designed to block translation by preventing binding between πbosomes and mRNA. In one alternative, a library of nucleic acid molecules or fragments thereof may be screened to identify those which specifically bind a regulatory, nontranslated sequence . Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA The mechanism of πbozyme action involves sequence-specific hybridization of the πbozyme molecule to complementary target RNA followed by endonucleolytic cleavage at sites such as GUA, GUU, and GUC Once such sites are identified, an ohgonucleotide with the same sequence may be evaluated for secondary structural features which would render the ohgonucleotide inoperable The suitability of candidate targets may also be evaluated by testing their hybridization with complementary oligonucleotides using πbonuclease protection assays Complementary nucleic acids and ribozymes of the invention may be prepared via recombinant expression, in vitro or in vivo, or using solid phase phosphoramidite chemical synthesis In addition, RNA molecules may be modified to increase intracellular stability and half-life by addition of flanking sequences at the 5 ' and/or 3 ' ends of the molecule or by the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule Modification is inherent in the production of PNAs and can be extended to other nucleic acid molecules. Either the inclusion of nontraditional bases such as inosine, queosine, and wybutosme, and or the modification of ademne, cytidine, guamne, thyπune, and undine with acetyl-, methyl-, thio- groups renders the molecule less available to endogenous endonucleases. Screemng Assays The nucleic acid molecule encoding the mammahan protein may be used to screen a library of molecules for specific binding affinity. The libraries may be DNA molecules, RNA molecules, PNAs, peptides, proteins such as transcription factors, enhancers, repressors, and other hgands which regulate the activity, replication, transcription, or translation of the nucleic acid molecule in the biological system. The assay involves combimng the mammalian nucleic acid molecule or a fragment thereof with the library of molecules under conditions allowing specific binding, and detecting specific binding to identify at least one molecule which specifically binds the nucleic acid molecule. Similarly the mammalian protein or a portion thereof may be used to screen libranes of molecules in any of a variety of screemng assays. The portion of the protein employed in such screemng may be free in solution, affixed to an abiotic or biotic substrate (e.g. borne on a cell surface), or located lntracellularly. Specific binding between the protein and molecule may be measured Depending on the kind of library being screened, the assay may be used to identify DNA, RNA, or PNA molecules, agonists, antagonists, antibodies, immunoglobulins. inhibitors, peptides, proteins, drugs, or any other ligand, which specifically binds the protein One method for high throughput screemng using very small assay volumes and very small amounts of test compound is described in USPN 5,876,946, incorporated herein by reference, which screens large numbers of molecules for enzyme inhibition or receptor binding Purification of Ligand The nucleic acid molecule or a fragment thereof may be used to purify a ligand from a sample. A method for using a mammalian nucleic acid molecule or a fragment thereof to purify a ligand would involve combimng the nucleic acid molecule or a fragment thereof with a sample under conditions to allow specific binding, detecting specific binding, recovering the bound protein, and using an appropriate agent to separate the nucleic acid molecule from the purified ligand Similarly, the protein or a portion thereof may be used to purify a ligand from a sample A method for using a mammalian protein or a portion thereof to purify a ligand would involve combimng the protein or a portion thereof with a sample under conditions to allow specific binding, detecting specific binding between the protein and ligand, recovering the bound protein, and using an appropπate chaotropic agent to separate the protein from the purified ligand. Pharmacology Pharmaceutical compositions are those substances wherein the active ingredients are contained in an effective amount to achieve a desired and intended purpose. The determination of an effective dose is well within the capability of those skilled in the art For any compound, the therapeutically effective dose may be estimated initially either in cell culture assays or in ammal models The ammal model is also used to achieve a desirable concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans A therapeutically effective dose refers to that amount of protein or inhibitor which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity of such agents may be determined by standard pharmaceutical procedures in cell cultures or expenmental animals, e.g , ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it may be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indexes are preferred. The data obtained from cell culture assays and ammal studies are used in formulating a range of dosage for human use. MODEL SYSTEMS Ammal models may be used as bioassays where they exhibit a toxic response similar to that of humans and where exposure conditions are relevant to human exposures Mammals are the most common models, and most toxicity studies are performed on rodents such as rats or mice because of low cost, availability, and abundant reference toxicology Inbred rodent strains provide a convement model for investigation of the physiological consequences of under- or over-expression of genes of interest and for the development of methods for diagnosis and treatment of diseases A mammal inbred to over-express a particular gene (for example, secreted in milk) may also serve as a convement source of the protein expressed by that gene Toxicology Toxicology is the study of the effects of agents on living systems The majority of toxicity studies are performed on rats or mice to help predict the effects of these agents on human health Observation of qualitative and quantitative changes in physiology, behavior, homeostatic processes, and lethality are used to generate a toxicity profile and to assess the consequences on human health following exposure to the agent Genetic toxicology identifies and analyzes the ability of an agent to produce genetic mutations Genotoxic agents usually have common chemical or physical properties that facilitate interaction with nucleic acids and are most harmful when chromosomal aberrations are passed along to progeny Toxicological studies may identify agents that increase the frequency of structural or functional abnormalities in progeny if admimstered to either parent before conception, to the mother during pregnancy, or to the developing orgamsm. Mice and rats are most frequently used in these tests because of their short reproductive cycle which produces the number of orgamsms needed to satisfy statistical requirements. Acute toxicity tests are based on a single administration of the agent to the subject to determine the symptomology or lethality of the agent Three experiments are conducted 1 ) an initial dose-range-finding experiment, 2) an experiment to narrow the range of effective doses, and 3) a final experiment for establishing the dose-response curve. Prolonged toxicity tests are based on the repeated administration of the agent. Rat and dog are commonly used in these studies to provide data from species in different families With the exception of carcinogenesis, there is considerable evidence that daily administration of an agent at high-dose concentrations for periods of three to tour months will reveal most forms of toxicity in adult ammals. Chrome toxicity tests, with a duration of a year or more, are used to demonstrate either the absence of toxicity or the carcinogenic potential of an agent When studies are conducted on rats, a mimmum of three test groups plus one control group are used, and ammals are examined and monitored at the outset and at intervals throughout the experiment. Transgemc Ammal Models Transgemc rodents which over-express or under-express a gene of interest may be inbred and used to model human diseases or to test therapeutic or toxic agents (See USPN 4,736,866. USPN 5,175,383, and USPN 5,767,337, incorporated herein by reference) In some cases, the introduced gene may be activated at a specific time in a specific tissue type during fetal development or postnatally. Expression of the transgene is momtored by analysis of phenotype or tissue-specific mRNA expression, in transgemc ammals before, during, and after being challenged with experimental drug therapies Embryomc Stem Cells Embryonic stem cells (ES) isolated from rodent embryos retain the potential to form an embryo When ES cells are placed inside a carrier embryo, they resume normal development and contribute to all tissues of the live-born ammal. ES cells are the preferred cells used in the creation of experimental knockout and knockin rodent strains Mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and are grown under culture conditions well known in the art Vectors for knockout strains contain a disease gene candidate modified to include a marker gene which disrupts transcription and/or translation in vivo The vector is introduced into ES cells by transformation methods such as electroporation, hposome delivery, microinjection, and the like which are well known in the art The endogenous rodent gene is replaced by the disrupted disease gene through homologous recombination and integration during cell division Then transformed ES cells are selected under conditions, identified, and preferably microinjected into mouse cell blastocysts such as those trom the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams and the resulting chimeπc progeny are genotyped and bred to produce heterozygous or homozygous strains ES cells are also used to study the differentiation of various cell types and tissues in vitro, such as neural cells, hematopoietic lineages, and cardiomyocytes (Bain et al. (1995) Dev Biol 168 342-357, Wiles and Keller (1991) Development 111.259-267, and Klug et al (1996) J Chn Invest 98.216-224) Recent developments demonstrate that ES cells deπved from human blastocysts may also be mampulated in vitro to differentiate into eight separate cell lineages, including endoderm, mesoderm, and ectodermal cell types (Thomson (1998) Science 282.1145-1147). Knockout Analysis In gene knockout analysis, a region of a human disease gene candidate is enzymatically modified to include a non-mammalian gene such as the neomycin phosphotransferase gene (neo, Capecchi (1989) Science 244.1288-1292) The inserted coding sequence disrupts transcription and translation of the targeted gene and prevents biochemical synthesis of the disease candidate protein The modified gene is transformed into cultured embryomc stem cells (described above), the transformed cells are injected into rodent blastulae, and the blastulae are implanted into pseudopregnant dams Transgemc progeny are crossbred to obtain homozygous inbred lines Knockin Analysis Totipotent ES cells, present in the early stages of embryomc development, can be used to create knockin humanized ammals (pigs) or transgemc ammal models (mice or rats) of human diseases. With knockin technology, a region of a human gene is injected into ammal ES cells, and the human sequence integrates into the ammal cell genome by recombination Totipotent ES cells which contain the integrated human gene are handled as described above Inbred ammals are studied and treated to obtain information on the analogous human condition These methods have been used to model several human diseases. (See, e g., Lee et al. (1998) Proc Natl. Acad. Sci. 95.H371-11376, Baudoin et al (1998) Genes Dev 12.1202-1216, and Zhuang et al (1998) Mol Cell Biol 18 3340- 3349) Non-Human Primate Model The field of ammal testing deals with data and methodology from basic sciences such as physiology, genetics, chemistry, pharmacology and statistics These data are paramount in evaluating the effects of therapeutic agents on non-human primates as they can be related to human health Monkeys are used as human surrogates in vaccine and drug evaluations, and their responses are relevant to human exposures under similar conditions. Cynomolgus monkeys (Macaca fasciculaπs, Macaca mulatta) and common marmosets (Callithπx jacchus) are the most common non-human primates (NHPs) used in these investigations. Since great cost is associated with developing and maintaining a colony of NHPs, early research and toxicological studies are usually carried out in rodent models. In studies using behavioral measures such as drug addiction, NHPS are the first choice test ammal. In addition, NHPS and individual humans exhibit differential sensitivities to many drugs and toxins and can be classified as "extensive metabohzers" and "poor metabohzers" of these agents In additional embodiments, the nucleic acid molecules which encode the mammalian protein may be used in any molecular biology techmques that have yet to be developed, provided the new techmques rely on properties of nucleic acid molecules that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions. EXAMPLES It is to be understood that this invention is not limited to the particular machines, materials and methods described. Although particular embodiments are described, equivalent embodiments may be used to practice the invention The described embodiments are not intended to limit the scope of the invention which is limited only by the appended claims The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention. For purposes of example, the preparation of the human kidney cDNA library, KIDNNOT20, is described. I Representative cDNA sequence preparation The human kidney cDNA library KIDNNOT20 was constructed from tissue obtained from a 43-year-old Caucasian male during nephroureterectomy and unilateral left adrenalectomy. The frozen tissue was homogenized and lysed in TRIZOL reagent (1 g tissue/10 ml TRIZOL; Life 5 Technologies), a monophasic solution of phenol and guanidine isothiocyanate, using a POLYTRON homogenizer (PT-3000; Brinkmann Instruments, Westbury NY). Following homogenization, chloroform was added (1 :5 v/v chloroform:homogenate), and the lysate was centrifuged. The aqueous layer was removed, and the RNA was precipitated with isopropanol. The RNA was resuspended in DEPC -treated water and digested with DNase I (Life Technologies) for 25 min at 10 37°C. The RNA was re-extracted with acid phenol-chloroform, pH 4J, and precipitated using 0.3M sodium acetate and 2.5 volumes ethanol. Messenger RNA (mRNA) was isolated using the OLIGOTEX kit (Qiagen, Valencia CA) and used to construct the cDNA library. The mRNA was handled according to the recommended protocols in the SUPERSCRIPT plasmid system (Life Technologies) which contains a Notl primer- 15 adaptor designed to prime the first strand cDNA synthesis at the poly(A) tail of mRNAs. Double stranded cDNA was blunted, ligated to EcoRI adaptors, and digested with Notl (New England Biolabs, Beverly MA). The cDNAs were fractionated on a SEPHAROSE CL-4B column (Amersham Pharmacia Biotech), and those cDNAs exceeding 400 bp were ligated into the Notl and EcoRI sites of the pINCY 1 plasmid (Incyte Pharmaceuticals, Palo Alto CA). The plasmid was transformed into 20 competent DH5α cells (Life Technologies) or ELECTROMAX DH10B cells (Life Technologies). Plasmid DNA was released from the cells and purified using the REAL Prep 96 plasmid kit (Qiagen). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Temfic Broth (Life Technologies) with carbenicillin at 25 mg/1 and glycerol at 0.4%; 2) after inoculation, the cells were cultured for 19 hours and then lysed 25 with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C. The cDNAs were prepared using the MICROLAB 2200 system (Hamilton, Reno NV) in combination with the DNA ENGINE thermal cyclers (MJ Research) and sequenced by the method of 30 Sanger, F. and A.R. Calcine (1975; J. Mol. Biol. 94:441-448) using an ABI PRISM 377 sequencing system (Perkin Elmer). Most of the isolates were sequenced according to standard ABI protocols and kits (Perkin Elmer) with solution volumes of 0.25x - l.Ox concentrations. In the alternative, cDNAs were sequenced using solutions and dyes from Amersham Pharmacia Biotech. II Identification, Extension, Assembly, and Analyses 35 The consensus sequence (SEQ ID NO: 10) was assembled from Incyte clones (SEQ ID NOs.6-9) from the ZOOSEQ database (Incyte Pharmaceuticals) of rat cDNA sequences with homology to mouse NG20 (SEQ ID NO.12) and used to identify additional sequences in the LIFESEQ database (Incyte Pharmaceuticals) related to lipocalin family proteins The first pass cDNAs, SEQ ID Nos.3-5, were assembled using Phrap to produce SEQ ID NO.l Translation of SEQ ID NO 1 and 10 using MACDNASIS PRO software (Hitachi Software Engineering) elucidated the coding regions, SEQ ID NO.2 and 11. The nucleic acid and amino acid sequences were queried against databases such as the GenBank databases, SwissProt, BLOCKS, PRINTS, Prosite, and PFAM using BLAST. Motifs and HMM algorithms were used to perform functional analyses, and the antigemc index (Jameson- Wolf analysis) was determined using LASERGENE software (DNASTAR) III Sequence Similarity Sequence similarity was calculated as percent identity based on comparisons between at least two nucleic acid molecules or amino acid sequences using the clustal method of the MEGALIGN program (DNASTAR) The clustal method uses an algonthm which groups sequences into clusters by examining the distances between all pairs After the clusters are aligned pairwise, they are realigned in groups. Percent similarity between two sequences, sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of very low or zero similarity between the two sequences are not included IV Northern Analysis Northern analysis is a laboratory techmque used to detect the presence of a transcript of a gene and involves the hybridization of a labeled probe to a membrane on which RNAs from a particular cell type or tissue have been bound. Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). Sequence-based analysis is much faster than membrane-based hybridization, and the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score which is defined as: (percent sequence identity x percent maximum BLAST score) divided by 100. The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1 % to 2% error, and with a product score of at least 70, the match will be exact. Similar or related molecules are usually identified by selecting those which show product scores between 8 and 40. The results of northern analyses are reported as a percentage distribution of libraπes in which the transcript encoding the mammalian protein occurred. Analysis involved the categorization of cDNA libraries by organ tissue and disease The organ tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease categories included cancer, inflammation/trauma, cell proliferation, and neurological For each category, the number of libraries expressing the sequence was counted and divided by the total number of libraπes across all categories V Extension of Nucleic Acid Molecules At least one of the nucleic acid molecules used to assemble SEQ ID NOs 1 and 10 was produced by extension of an Incyte cDNA clone using ohgonucleotide primers One primer was synthesized to initiate 5 " extension of the known fragment, and the other, to initiate 3' extension The initial primers were designed using OLIGO 4 06 software (National Biosciences) to be about 22 to 30 nucleotides in length, to have a GC content of about 50%, and to anneal to the target sequence at temperatures of about 55 °C to about 68 °C Any fragment which would result in hairpin structures and primer-primer dimeπzations was avoided Selected human cDNA libraries were used to extend the molecule If more than one extension is needed, additional or nested sets of primers are designed High fidelity amplification was obtained by performing PCR in 96-well plates using the DNA ENGINE thermal cycler (MJ Research). The reaction mix contained DNA template, 200 nmol of each primer reaction buffer contaimng Mg 2+ , (NH 4 ) 2 S0 4 , and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair selected from the plasmid. Step 1 94°C, 3 min, Step 2- 94 °C, 15 sec; Step 3. 60°C, 1 min; Step 4. 68 °C, 2 min, Step 5. Steps 2, 3, and 4 repeated 20 times, Step 6 68 °C, 5 min, Step 7. storage at 4 °C In the alternative, parameters for the primer pair, T7 and SK+ (Stratagene), were as follows: Step 1. 94 °C, 3 min, Step 2: 94°C, 15 sec, Step 3. 57 °C, 1 mm, Step 4. 68 °C, 2 min; Step 5. Steps 2, 3, and 4 repeated 20 times; Step 6. 68 °C, 5 mm, Step 7 storage at 4 °C The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v), Molecular Probes) dissolved in IX TE and 0.5 μl of undiluted PCR product into each well of an opaque fluoπmeter plate (Corning Costar, Acton MA) and allowing the DNA to bind to the reagent The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 l to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in producing longer sequence The extended sequences were desalted, concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and somcated or sheared pnor to rehgation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested fragments were separated on about 0.6- 0.8% agarose gels, fragments were excised as visualized under UV light, and agar removed/digested with AGARACE (Promega) Extended fragments were rehgated using T4 DNA hgase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transformed into competent E coh cells Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overmght at 37 °C in 384-well plates in LB/2x carbenicilhn liquid media The cells were lysed, and DNA was amplified using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters Step 1 94°C, 3 min, Step 2 94 °C, 15 sec, Step 3 60 °C, 1 min, Step 4 72 °C, 2 min, Step 5 steps 2, 3, and 4 repeated 29 times, Step 6 72 °C, 5 min, Step 7 storage at 4 °C DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above Samples with low DNA recoveries were reamp fied using the conditions described above Samples were diluted with 20% dimethysulphoxide (1 2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer) In like manner, the nucleic acid molecule of SEQ ID NOs 1 or 10 is used to obtain regulatory sequences using the procedure above, oligonucleotides designed for outward extension, and a genomic DNA library VI Labeling of Probes and Hybridization Analyses Nucleic acids are isolated from a biological source and applied to a substrate for standard hybndization protocols by one of the following methods A mixture of target nucleic acids, a restriction digest of genomic DNA, is fractionated by electrophoresis through an 0 7% agarose gel in lxTAE [Tπs-acetate-ethylenediamine tetraacetic acid (EDTA)] running buffer and transferred to a nylon membrane by capillary transler using 20x saline sodium citrate (SSC) Alternatively, the target nucleic acids are individually ligated to a vector and inserted into bacterial host cells to form a library Target nucleic acids are arranged on a substrate by one of the following methods In the first method, bactenal cells contaimng individual clones are robotically picked and arranged on a nylon membrane The membrane is placed on bactenal growth medium, LB agar contaimng carbenicilhn, and incubated at 37°C tor 16 hours Bacterial colomes are denatured, neutralized, and digested with proteinase K Nylon membranes are exposed to UV irradiation in a STRATALINKER UV-crosslinker (Stratagene) to cross-link DNA to the membrane In the second method, target nucleic acids are amplified from bacterial vectors by thirty cycles of PCR using pnmers complementary to vector sequences flanking the insert Amplified target nucleic acids are purified using SEPHACRYL-400 beads (Amersham Pharmacia Biotech) Purified target nucleic acids are robotically arrayed onto a glass microscope slide (Coming Science Products, Corning NY) The slide is previously coated with 0.05% aminopropyl silane (Sigma- Aldrich, St Louis MO) and cured at 110°C The anayed glass slide (microarray) is exposed to UV irradiation in a STRATALINKER UV-crosslinker (Stratagene). cDNA probes are made from mRNA templates. Five micrograms of mRNA is mixed with 1 μg random primer (Life Technologies), incubated at 70°C for 10 minutes, and lyopfulized The lyophihzed sample is resuspended in 50 μl of lx first strand buffer (cDNA Synthesis systems, Life Technologies) contaimng a dNTP mix, [αJ 2 P]dCTP, dithiothreitol, and MMLV reverse transcriptase (Stratagene), and incubated at 42°C for 1-2 hours. After incubation, the probe is diluted with 42 |j] dH 2 0, heated to 95 °C for 3 minutes, and cooled on ice. mRNA in the probe is removed by alkaline degradation. The probe is neutralized, and degraded mRNA and unincorporated nucleotides are removed using a PROBEQUANT G-50 MicroColumn (Amersham Pharmacia Biotech) Probes can be labeled with fluorescent markers, Cy3-dCTP or Cy5-dCTP (Amersham Pharmacia Biotech), in place of the radionucleotide, [ 32 P]dCTP Hybridization is earned out at 65 °C in a hybridization buffer contaimng 0 5 M sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA After the substrate is incubated in hybridization buffer at 65 °C for at least 2 hours, the buffer is replaced with 10 ml of fresh buffer contaimng the probes. After incubation at 65 °C for 18 hours, the hybridization buffer is removed, and the substrate is washed sequentially under increasingly stnngent conditions, up to 40 mM sodium phosphate, 1% SDS, 1 mM EDTA at 65°C. To detect signal produced by a radiolabeled probe hybridized on a membrane, the substrate is exposed to a PHOSPHORIMAGER cassette (Amersham Pharmacia Biotech), and the image is analyzed using IMAGEQUANT data analysis software (Amersham Pharmacia Biotech) To detect signals produced by a fluorescent probe hybndized on a microarray, the substrate is examined by confocal laser microscopy, and images are collected and analyzed using GEMTOOLS gene expression analysis software (Incyte Pharmaceuticals) VII Complementary Nucleic Acid Molecules Molecules complementary to the nucleic acid molecule, or a fragment thereof, are used to detect, decrease, or inhibit gene expression. Although use of oligonucleotides compnsmg from about 15 to about 30 base pairs is described, the same procedure is used with larger or smaller fragments or their denvaϋves (PNAs) Oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and SEQ ID NOs.l and 3-10. To inhibit transcription by preventing promoter binding, a complementary ohgonucleotide is designed to bind to the most umque 5' sequence, most preferably about 10 nucleotides before the initiation codon of the open reading frame. To inhibit translation, a complementary ohgonucleotide is designed to prevent πbosomal binding to the mRNA encoding the mammalian protein. VIII Expression of the Mammalian Protein Expression and purification of the mammalian protein are achieved using bacterial or virus- based expression systems For expression in bacteria, cDNA is subcloned into a vector contaimng an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription Examples of such promoters include, but are not limited to, the trp-lac (tac) hybπd promoter and the T5 or T7 bacteπophage promoter in conjunction with the lac operator regulatory element Recombinant vectors are transformed into bacterial hosts, e g , BL21(DE3) Antibiotic resistant bacteria express the mammalian protein upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG) Expression in eukaryotic cells is achieved by infecting Spodoptera frugiperda (Sf9) insect cells with recombinant baculovirus, Autographica cahfornica nuclear polyhedrosis virus The polyhedπn gene of baculovirus is replaced with the mammalian cDNA by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates Viral infectivity is maintained and the strong polyhedπn promoter dπves high levels of cDNA transcription In most expression systems, the mammalian protein is synthesized as a fusion protein with, e g , glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG, permitting rapid, single- step, at finity-based punfication of recombinant fusion protein from crude cell lysates GST enables the punfication of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech) Following purification, the GST moiety can be proteolytically cleaved from the mammalian protein at specifically engineered sites FLAG, an 8-amιno acid peptide, enables lmmunoaffimty purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak) 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN) Methods for protein expression and punfication are discussed in Ausubel (supra, umt 16) Purified mammalian protein obtained by these methods can be used directly in the following activity assay IX Functional Assays Protein function is assessed by expressing the sequences encoding LCFP at physiologically elevated levels in mammalian cell culture The nucleic acid molecule is subcloned into PCMV SPORT vector (Life Technologies), which contains the strong cytomegalovirus promoter, and 5-10 μg of the vector is transformed into a endothehal or hematopoietic human cell line using transformation methods well known in the art An additional 1-2 μg of a plasmid contaimng sequence encoding CD64-GFP (Clontech) is co-transformed to provide a fluorescent marker to identify transformed cells using flow cytometry (FCM) The influence of the introduced genes on expression can be assessed using purified populations of these transformed cells. Since CD64-GFP, which is expressed on the surface of transformed cells, binds to conserved regions of human immunoglobulin G (IgG), the transformed cells is separated using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA is purified from the cells and analyzed by hybridization techniques. X Production of LCFP Specific Antibodies LCFP is purified using polyacrylamide gel electrophoresis and used to immunize mice or rabbits. Antibodies are produced using the protocols below. Alternatively, the amino acid sequence of LCFP is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity. An immunogenic epitope, usually found near the C-terminus or in a hydrophilic region is selected, synthesized, and used to raise antibodies. Typically, epitopes of about 15 residues in length are produced using an ABI 431 A Peptide synthesizer (Perkin-Elmer) using Fmoc-chemistry and coupled to KLH (Sigma-Aldrich) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester to increase immunogenicity. Rabbits are immunized with the epitope-KLH complex in complete Freund's adjuvant. Immunizations are repeated at intervals thereafter in incomplete Freund's adjuvant. After a minimum of seven weeks for mouse or twelve weeks for rabbit, antisera are drawn and tested for antipeptide activity. Testing involves binding the peptide to plastic, blocking with 1 % bovine serum albumin, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Methods well known in the art are used to determine antibody titer and the amount of complex formation. XI Purification of Naturally Occurring Protein Using Specific Antibodies Naturally occurring or recombinant mammalian protein is substantially purified by immunoaffinity chromatography using antibodies specific for the protein. An immunoaffinity column is constructed by covalently coupling the antibody to CNBr-activated SEPHAROSE resin (Amersham Pharmacia Biotech). Media containing the protein is passed over the immunoaffinity column, and the column is washed using high ionic strength buffers in the presence of detergent to allow preferential absorbance of the protein. After coupling, the protein is eluted from the column using a buffer of pH 2-3 or a high concentration of urea or thiocyanate ion to disrupt antibody/protein binding, and the protein is collected. XII Screening Molecules for Specific Binding with the Nucleic Acid Molecule or Protein The nucleic acid molecule, or fragments thereof, or the protein, or portions thereof, are labeled with 32 P-dCTP, Cy3-dCTP, or Cy5-dCTP (Amersham Pharmacia Biotech), or with BIODIPY or FITC (Molecular Probes, Eugene OR), respectively. Libraries of candidate molecules previously arranged on a substrate are incubated in the presence of labeled nucleic acid molecule or protein. After incubation under conditions for either a nucleic acid or amino acid sequence, the substrate is washed, and any position on the substrate retaining label, which indicates specific binding or complex formation, is assayed, and the binding molecule is identified Data obtained using different concentrations of the nucleic acid or protein are used to calculate affimty between the labeled nucleic acid or protein and the bound molecule XIII Demonstration of Protein Activity LCFP, or biologically active fragments thereof, are labeled with 1 5 I Bolton-Hunter reagent (Bolton et al (1973) Biochem. J. 133.529-539). Candidate ligand molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled LCFP, washed, and any wells with labeled LCFP complex are assayed. Data obtained using different concentrations of LCFP are used to calculate values for the number, affimty, and association of LCFP with the candidate ligand molecules Table 1 Comparison between Incyte rat and human nucleic acid molecules including their length, biological source, region of overlap with SEQ ID NO: l , and percent identity with SEQ ID NO: l (MEGALIGN program, DNASTAR).

Claims: What is claimed is 1 A substantially purified mammalian nucleic acid molecule and fragments thereof encoding the lipocalin family protein and portions thereof 2 Isolated and purified mammalian nucleic acid molecules comprising the nucleic acid sequence selected from SEQ ID NO 1 and SEQ ID NO 10 3. A fragment of the mammalian nucleic acid molecule of claim 1 selected from SEQ ID NOs 1 and 3-10 4 The complement of the nucleic acid molecule of claim 1 or a fragment thereof 5 The complement of a fragment of claim 3. 6 A probe which hybridizes under high stringency conditions to the mammalian nucleic acid molecule of claim 1 or a fragment thereof 7 An expression vector comprising at least a fragment of the mammalian nucleic acid molecule of claim 1 8 A host cell contaimng the expression vector of claim 7 9 A method for producing a protein, the method comprising the steps of (a) culturing the host cell of claim 8 under conditions for the expression of the protein, and (b) recovering the protein from the host cell culture 10 A method for detecting a mammalian nucleic acid molecule in a sample, the method comprising the steps of. (a) hybridizing the probe of claim 6 to at least one nucleic acid molecule in the sample, thereby forming a hybridization complex, and (b) detecting the hybridization complex, wherein the presence of the hybridization complex indicates the presence of the mammalian nucleic acid molecule in the sample 11. The method of claim 10 further comprising amplifying the nucleic acid molecule or a fragment thereof pnor to hybridization 12. A method of using a mammalian nucleic acid molecule or a fragment thereof to screen a library of molecules to identify at least one ligand which specifically binds the nucleic acid molecule, the method comprising: (a) providing a library of molecules, (b) combimng the nucleic acid molecule of claim 1 with a library of molecules under conditions to allow specific binding, and (c) detecting specific binding, thereby identifying a ligand which specifically binds the nucleic acid molecule. 13. The method of claim 12 wherein the library is selected from DNA molecules, RNA molecules, PNAs, peptides, and proteins 14 A ligand identified using the method of claim 12 which modulates the activity of the nucleic acid molecule. 15 A method of using a mammalian nucleic acid molecule or a fragment thereof to purify a ligand which specifically binds the nucleic acid molecule from a sample, the method comprising a) combimng mammalian nucleic acid molecule or a fragment thereof of claim 1 with a sample under conditions to allow specific binding, and b) detecting specific binding between the nucleic acid molecule and a ligand, c) recovering the bound nucleic acid molecule, and d) separating the nucleic acid molecule from the ligand, thereby obtaining purified ligand 16 An substantially purified mammalian lipocalin family protein or a portion thereof 17 An isolated and purified protein comprising the amino acid sequence selected from SEQ ID NO 2 and SEQ ID NO: 11. 18 A method for using a protein or a portion thereof to screen a library of molecules to identify at least one ligand which specifically binds the protein, the method comprising. (a) providing a library of molecules, (b) combimng the protein or a portion thereof of claim 16 with the library of molecules under conditions to allow specific binding, and (c) detecting specific binding, thereby identifying a ligand which specifically binds the protein. 19 The method of claim 18 wherein the library is selected from DNA molecules, RNA molecules, PNAs, peptides, proteins, agomsts, antagomsts, antibodies, immunoglobulins, inhibitors, drug compounds and pharmaceutical agents 20 A ligand identified using the method of claim 18 which modulates the activity of the mammalian protein. 21. A method of using a mammalian protein or a portion thereof to purify a hgand which specifically binds the protein from a sample, the method comprising a) combimng the protein or a portion thereof of claim 16 with a sample under conditions to allow specific binding, b) detecting specific binding between the protein and a ligand, c) recovenng the bound protein, and d) separating the protein from the ligand, thereby obtaimng purified ligand

Inventors: BAUGHN MARIAH R, MURRY LYNN E, TANG Y TOM, BAUGHN, MARIAH, R., MURRY, LYNN, E., TANG, Y., TOM
Applicants: BAUGHN MARIAH R, INCYTE GENOMICS INC, MURRY LYNN E, TANG Y TOM, BAUGHN, MARIAH, R., INCYTE GENOMICS, INC., MURRY, LYNN, E., TANG, Y., TOM
Application year: 2000
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33